[H-3]L-655,708, a novel ligand selective for the benzodiazepine site of GABA(A) receptors which contain the alpha 5 subunit

被引:158
作者
Quirk, K
Blurton, P
Fletcher, S
Leeson, P
Tang, F
Mellilo, D
Ragan, CI
McKernan, RM
机构
[1] DEPT BIOCHEM,HARLOW CM20 2QR,ESSEX,ENGLAND
[2] MERCK SHARP & DOHME LTD,RES LABS,HARLOW CM20 2QR,ESSEX,ENGLAND
[3] MERCK SHARP & DOHME LTD,RES LABS,DEPT CHEM,HARLOW CM20 2QR,ESSEX,ENGLAND
[4] DEPT DRUG METAB,RAHWAY,NJ
关键词
GABA(A) receptor; radioligand; alpha; 5-selective; benzodiazepine site; H-3]L-655,708;
D O I
10.1016/S0028-3908(96)00061-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
A compound (L-655,708) has been identified which has at least 50-fold selectivity for the benzodiazepine site on GABA(A) receptors containing an alpha 5 subunit over those containing an alpha 1, alpha 2, alpha 3 or alpha 6 subunit in combination with beta 3 and gamma 2. The compound was radiolabelled with tritium and investigated as a novel radioligand which recognizes the benzodiazepine site of GABA(A) receptors which contain the alpha 5 subunit. [H-3]L-655,708 labels one saturable and specific population of binding sites in rat hippocampus with a K-d of 2.4 +/- 0.7 nM and a B-max of 256 +/- 42 fmol/mg protein. The pharmacology of the binding site labelled was consistent with that of receptors present in cells transfected with alpha 5, beta 2 and gamma 2 and with receptors immunoprecipitated from rat brain with an alpha 5-selective antiserum. It is concluded that [H-3]L-655,708 is the first radioligand to date which is selective for any BZ2 subtype of the GABA(A) receptor and should provide a valuable tool for elucidating the structure and function of the alpha 5-containing GABA(A) receptor subtype. Copyright (C) 1996 Elsevier Science Ltd.
引用
收藏
页码:1331 / 1335
页数:5
相关论文
共 16 条
[1]   HIGH-AFFINITY [H-3] ZOLPIDEM BINDING IN THE RAT-BRAIN - AN IMIDAZOPYRIDINE WITH AGONIST PROPERTIES AT CENTRAL BENZODIAZEPINE RECEPTORS [J].
ARBILLA, S ;
ALLEN, J ;
WICK, A ;
LANGER, SZ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1986, 130 (03) :257-263
[2]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[3]  
GILLARD NP, 1994, BRIT J PHARMACOL, V112, pP258
[4]  
HADINGHAM KL, 1993, MOL PHARMACOL, V43, P970
[5]   GABA-A RECEPTOR SUBTYPES IMMUNOPURIFIED FROM RAT-BRAIN WITH ALPHA SUBUNIT-SPECIFIC ANTIBODIES HAVE UNIQUE PHARMACOLOGICAL PROPERTIES [J].
MCKERNAN, RM ;
QUIRK, K ;
PRINCE, R ;
COX, PA ;
GILLARD, NP ;
RAGAN, CI ;
WHITING, P .
NEURON, 1991, 7 (04) :667-676
[6]   THE PHARMACOLOGY OF THE BENZODIAZEPINE SITE OF THE GABA-A RECEPTOR IS DEPENDENT ON THE TYPE OF GAMMA-SUBUNIT PRESENT [J].
MCKERNAN, RM ;
WAFFORD, K ;
QUIRK, K ;
HADINGHAM, KL ;
HARLEY, EA ;
RAGAN, CI ;
WHITING, PJ .
JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, 1995, 15 (1-4) :173-183
[7]   GAMMA-AMINOBUTYRIC ACIDA RECEPTOR ALPHA-5-SUBUNIT CREATES NOVEL TYPE-II BENZODIAZEPINE RECEPTOR PHARMACOLOGY [J].
PRITCHETT, DB ;
SEEBURG, PH .
JOURNAL OF NEUROCHEMISTRY, 1990, 54 (05) :1802-1804
[8]   TYPE-I AND TYPE-II GABAA-BENZODIAZEPINE RECEPTORS PRODUCED IN TRANSFECTED CELLS [J].
PRITCHETT, DB ;
LUDDENS, H ;
SEEBURG, PH .
SCIENCE, 1989, 245 (4924) :1389-1392
[9]  
SIEGHART W, 1995, PHARMACOL REV, V47, P181
[10]   FUNCTIONAL DOMAINS OF GABA(A) RECEPTORS [J].
SMITH, GB ;
OLSEN, RW .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (05) :162-168